An Observational Study to Determine the Clinical Cure Rate of Therapeutic up Front Shave Removal of Basal Cell Carcinoma of the Skin With Long Term Follow up to Evaluate Recurrence

Basal cell carcinoma (BCC) is the most common skin cancer in the world, with approximately
3.5 million cases a year diagnosed in the United States. BCC are indolent and metastasis is
extremely rare, occurring in less than .003% of cases. However, due to the high prevalence of
this tumor, significant health care resources are used in its diagnosis and treatment.
Management of BCC in many instances includes clinical evaluation of the lesion, biopsy or
sampling of the lesion to confirm the diagnosis, followed by definitive treatment at a later
date through surgical excision or medical therapy. A clinical diagnosis of BCC can be made
with a high degree of confidence based on clinical findings. The investigators propose that
by performing a deep shave removal of the entire lesion with histologically negative margins,
based upon clinical diagnosis, complete removal can be achieved without the need for follow
up therapy. Deep shave removal at time of initial evaluation is performed in many instances.
The investigators believe that doing a deep shave removal would substantially reduce the
number of second procedures that need to be done, thereby reducing treatment costs and
patients' need to return for an additional procedure. In doing a deep shave removal,
clinically diagnosed BCC will be removed entirely with narrow 2-3 mm margins, the tissue
specimen will then be sent to the pathologist to confirm that margins are clear. The
investigators will consider treatment of the BCC to be complete at this point and will follow
the patients clinically.

Inclusion Criteria:

- Patients 18 years or older that are determined by an investigator to have a lesion
that is highly likely to be a BCC, less than or equal to 1.0cm in largest diameter,
based on clinical examination located in the trunk or extremities, proximal to the
wrist and ankles

- Subject is able to give informed consent

- Subject is able to commit to 6 month follow up visit

Exclusion Criteria:

- BCC > 1cm in diameter on any one axis.

- Immunosuppressed patients

- Subjects with neutropenia

- Organ transplant patients

- Subjects with a life expectancy less than year

- Patients taking immunosuppressive medications, including prednisone at a dose of 10mg
or greater with an expected duration greater than 4 weeks, azathioprine, mycophenolate
mofetil, cyclosporine, oral Tacrolimus, any Tumor Necrosis Factor (TNF)-alpha
inhibitor, ustekinumab, rituximab, or any other medication in the judgement of the
investigator could results in clinically meaningful immunosuppression of the subject

- Basal cell carcinomas that have infiltrative or morpheaform characteristics based on
clinical examination

- Subjects unable to provide informed consent

- Subjects unable to commit to 6 month follow up